Novartis to invest $55m in Relation.

Novartis, a Swiss multinational pharmaceutical company, agreed to invest $55m in Relation, a technology-enabled biopharmaceutical company developing medicines across immunology, metabolic and bone diseases. “Our collaboration with Relation will combine complementary expertise, technologies and capabilities to advance new options for patients living with atopic diseases," Fiona Marshall, President of Biomedical Research.